Goodwin Procter LLP advised Evox Therapeutics on the deal.Evox Therapeutics, leading exosome therapeutics company, announced its £69.2 million Series C financing round. The financing was significantly oversubscribed…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
